Benefits seen within days for both frequency and severity of symptoms<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, May 20, 2024 (HealthDay News) — Fezolinetant is safe and effective for moderate-to-severe vasomotor symptoms (VMS), according to a study presented at the annual European Congress of Endocrinology, hosted by the European Society of Endocrinology from May 11 to 14\u00a0in Stockholm.<\/p>\n
Angelica Lind \u00a9n Hirschberg, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues assessed early response to fezolinetant in terms of frequency and severity of moderate-to-severe VMS. The analysis included 453 women unsuitable for hormone therapy participating in the 24-week placebo-controlled DAYLIGHT study.<\/p>\n
The researchers found that compared with those taking placebo, participants treated with fezolinetant (45 mg) had a greater reduction in the daily mean change in frequency of moderate-to-severe VMS from baseline through the first week of treatment (day 7 least squares mean difference, \u00e2\u0080\u00932.20). There was a decrease observed in VMS frequency from days 1 to 6, with the strongest decrease seen during the first three days. Additionally, fezolinetant was associated with greater reduction in the daily mean change in VMS severity from days 2 to 7 compared with placebo (day 7 least squares mean difference, \u00e2\u0080\u00930.17). Through week 24, improvements in VMS frequency and severity were sustained. There were no safety signals of concern reported through week 24.<\/p>\n
“An effect on VMS frequency was seen as early as day 1 and maintained through the 24-week placebo-controlled period, demonstrating a rapid onset of action and sustained efficacy with fezolinetant treatment,” the authors write.<\/p>\n
The study was funded by Astellas Pharma, the manufacturer of fezolinetant.<\/p>\n
Press Release<\/a><\/p>\n